vs
EXACT SCIENCES CORP（EXAS）与MAXIMUS, INC.（MMS）财务数据对比。点击上方公司名可切换其他公司
MAXIMUS, INC.的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），MAXIMUS, INC.净利率更高（30.2% vs -9.8%，领先40.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs -2.8%），MAXIMUS, INC.自由现金流更多（$450.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
MAXIMUS是美国一家政府服务企业，业务覆盖美国、加拿大、英国等国家，为医疗补助、联邦医疗保险、医改、就业帮扶、学生贷款服务等各类政府项目提供行政及配套服务。公司总部位于弗吉尼亚州泰森斯，现有员工3.96万名，2024财年营收达53亿美元。
EXAS vs MMS — 直观对比
营收规模更大
MMS
是对方的1.5倍
$878.4M
营收增速更快
EXAS
高出25.9%
-2.8%
净利率更高
MMS
高出40.0%
-9.8%
自由现金流更多
MMS
多$329.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | $394.0M |
| 毛利率 | 70.1% | 26.2% |
| 营业利润率 | -9.4% | 11.4% |
| 净利率 | -9.8% | 30.2% |
| 营收同比 | 23.1% | -2.8% |
| 净利润同比 | 90.1% | -4.1% |
| 每股收益（稀释后） | $-0.45 | $7.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMMS
| Q1 26 | — | $1.3B | ||
| Q4 25 | $878.4M | $1.3B | ||
| Q3 25 | $850.7M | $1.3B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.4B | ||
| Q3 24 | $708.7M | $1.3B | ||
| Q2 24 | $699.3M | $1.3B |
净利润EXASMMS
| Q1 26 | — | $394.0M | ||
| Q4 25 | $-86.0M | $93.9M | ||
| Q3 25 | $-19.6M | $75.3M | ||
| Q2 25 | $-1.2M | $106.0M | ||
| Q1 25 | $-101.2M | $96.6M | ||
| Q4 24 | $-864.6M | $41.2M | ||
| Q3 24 | $-38.2M | $72.5M | ||
| Q2 24 | $-15.8M | $89.8M |
毛利率EXASMMS
| Q1 26 | — | 26.2% | ||
| Q4 25 | 70.1% | 23.7% | ||
| Q3 25 | 68.6% | 25.3% | ||
| Q2 25 | 69.3% | 26.7% | ||
| Q1 25 | 70.8% | 24.9% | ||
| Q4 24 | 69.0% | 21.5% | ||
| Q3 24 | 69.4% | 22.9% | ||
| Q2 24 | 69.8% | 25.3% |
营业利润率EXASMMS
| Q1 26 | — | 11.4% | ||
| Q4 25 | -9.4% | 10.9% | ||
| Q3 25 | -3.0% | 9.3% | ||
| Q2 25 | -0.3% | 12.3% | ||
| Q1 25 | -13.6% | 11.2% | ||
| Q4 24 | -122.8% | 6.2% | ||
| Q3 24 | -5.6% | 8.5% | ||
| Q2 24 | -3.8% | 10.8% |
净利率EXASMMS
| Q1 26 | — | 30.2% | ||
| Q4 25 | -9.8% | 7.0% | ||
| Q3 25 | -2.3% | 5.7% | ||
| Q2 25 | -0.1% | 7.9% | ||
| Q1 25 | -14.3% | 7.1% | ||
| Q4 24 | -121.2% | 2.9% | ||
| Q3 24 | -5.4% | 5.5% | ||
| Q2 24 | -2.3% | 6.8% |
每股收益（稀释后）EXASMMS
| Q1 26 | — | $7.27 | ||
| Q4 25 | $-0.45 | $1.70 | ||
| Q3 25 | $-0.10 | $1.27 | ||
| Q2 25 | $-0.01 | $1.86 | ||
| Q1 25 | $-0.54 | $1.69 | ||
| Q4 24 | $-4.69 | $0.69 | ||
| Q3 24 | $-0.21 | $1.18 | ||
| Q2 24 | $-0.09 | $1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $157.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.7B |
| 总资产 | $5.9B | $4.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASMMS
| Q1 26 | — | $157.5M | ||
| Q4 25 | $964.7M | $137.6M | ||
| Q3 25 | $1.0B | $222.4M | ||
| Q2 25 | $858.4M | $59.8M | ||
| Q1 25 | $786.2M | $108.1M | ||
| Q4 24 | $1.0B | $72.7M | ||
| Q3 24 | $1.0B | $183.1M | ||
| Q2 24 | $946.8M | $102.8M |
股东权益EXASMMS
| Q1 26 | — | $1.7B | ||
| Q4 25 | $2.4B | $1.7B | ||
| Q3 25 | $2.5B | $1.7B | ||
| Q2 25 | $2.5B | $1.8B | ||
| Q1 25 | $2.4B | $1.7B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $3.2B | $1.8B | ||
| Q2 24 | $3.2B | $1.8B |
总资产EXASMMS
| Q1 26 | — | $4.2B | ||
| Q4 25 | $5.9B | $4.2B | ||
| Q3 25 | $5.9B | $4.1B | ||
| Q2 25 | $5.8B | $4.5B | ||
| Q1 25 | $5.7B | $4.2B | ||
| Q4 24 | $5.9B | $4.1B | ||
| Q3 24 | $6.7B | $4.1B | ||
| Q2 24 | $6.7B | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $450.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 34.5% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $643.0M |
8季度趋势，按日历期对齐
经营现金流EXASMMS
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $-244.4M | ||
| Q3 25 | $219.9M | $649.4M | ||
| Q2 25 | $89.0M | $-182.7M | ||
| Q1 25 | $30.8M | $42.7M | ||
| Q4 24 | $47.1M | $-80.0M | ||
| Q3 24 | $138.7M | $163.8M | ||
| Q2 24 | $107.1M | $199.3M |
自由现金流EXASMMS
| Q1 26 | — | $450.0M | ||
| Q4 25 | $120.4M | $-250.7M | ||
| Q3 25 | $190.0M | $641.8M | ||
| Q2 25 | $46.7M | $-198.2M | ||
| Q1 25 | $-365.0K | $25.5M | ||
| Q4 24 | $10.7M | $-103.0M | ||
| Q3 24 | $112.6M | $131.9M | ||
| Q2 24 | $71.2M | $164.6M |
自由现金流率EXASMMS
| Q1 26 | — | 34.5% | ||
| Q4 25 | 13.7% | -18.6% | ||
| Q3 25 | 22.3% | 48.7% | ||
| Q2 25 | 5.8% | -14.7% | ||
| Q1 25 | -0.1% | 1.9% | ||
| Q4 24 | 1.5% | -7.3% | ||
| Q3 24 | 15.9% | 10.0% | ||
| Q2 24 | 10.2% | 12.5% |
资本支出强度EXASMMS
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 3.5% | 0.6% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 4.4% | 1.3% | ||
| Q4 24 | 5.1% | 1.6% | ||
| Q3 24 | 3.7% | 2.4% | ||
| Q2 24 | 5.1% | 2.6% |
现金转化率EXASMMS
| Q1 26 | — | — | ||
| Q4 25 | — | -2.60× | ||
| Q3 25 | — | 8.63× | ||
| Q2 25 | — | -1.72× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | -1.94× | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | 2.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MMS
暂无分部数据
